Method of improving diastolic dysfunction

• US 9,114,133 B2
• Filed: 10/24/2012
• Issued: 08/25/2015
• Est. Priority Date: 08/25/2006
• Status: Expired due to Fees

• Current Assignee: Board of Trustees of The University of Illinois, United States Department of Veterans Affairs (Government of the United States of America)
• Original Assignee: Board of Trustees of The University of Illinois, US Dept. Of Veterans Affairs
• Inventors: Dudley, Samuel C. Jr.
• Primary Examiner(s): Gembeh, Shirley V
• Application Number:
  US13/658,943
• Publication Number:
  US 20130065903A1
• Time in Patent Office: 1,035 Days
• Field of Search: 514/249
• US Class Current: 1/1
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 38/44 Oxidoreductases (1)
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

A method of treating, preventing, reversing, or ameliorating diastolic dysfunction includes reducing S-glutathionylated myosin binding protein-C (MyBP-C) level by administering to a host in need thereof a therapeutically effective amount of tetrahydrobiopterin (BH₄).

Claims

1. A method of treating, reversing, or ameliorating diastolic dysfunction in a host with normal systolic function, comprising:

a) providing a host with normal systolic function with an ejection fraction of 50% or greater, and in need of treating, reversing, or ameliorating diastolic dysfunction; and

b) reducing S-glutathionylated myosin binding protein-C (MyBP-C) level by administering to the host a therapeutically effective amount of tetrahydrobiopterin (BH₄).

2. The method of claim 1, wherein the step of administering comprises:

administering BH₄ in at least one form selected from the group consisting of a dietary supplement, a composition, a pharmaceutical composition, and a combination thereof.

3. The method of claim 1, wherein the step of administering comprises:

administering BH₄ orally.

4. The method of claim 1, wherein the host is a human.

5. The method of claim 1, wherein the host is an animal.

6. A method of treating, preventing, reversing, or ameliorating diastolic dysfunction, comprising:

modulating post-translational modification of myosin binding protein-C (MyBP-C) level by administering to a host in need thereof a therapeutically effective amount of tetrahydrobiopterin (BH4).

7. The method of claim 6, wherein the step of administering comprises:

administering BH4 in at least one form selected from the group consisting of a dietary supplement, a composition, a pharmaceutical composition, and a combination thereof.

8. The method of claim 6, wherein the step of administering comprises:

administering BH4 orally.

9. The method of claim 6, wherein the host is a human.

10. The method of claim 6, wherein the host is an animal.